Entire patient cohort characteristics and uses
| Clinical condition . | Patients, n . | Group no. . | Use . |
|---|---|---|---|
| Training set | |||
| aGvHD | 13 | 1 | Training set to develop GvHD pattern |
| Control | 50 | 1 | Training set to develop GvHD pattern |
| Total | 63 | ||
| Chronic renal disease | |||
| Healthy | 20 | 2 | Set to develop GvHD pattern specificity |
| IgAN | 24 | 2 | Set to develop GvHD pattern specificity |
| DN | 11 | 2 | Set to develop GvHD pattern specificity |
| FSGS | 6 | 2 | Set to develop GvHD pattern specificity |
| MCD | 8 | 2 | Set to develop GvHD pattern specificity |
| MGN | 5 | 2 | Set to develop GvHD pattern specificity |
| Vasculitis | 11 | 2 | Set to develop GvHD pattern specificity |
| SLE | 4 | 2 | Set to develop GvHD pattern specificity |
| Total | 71 | ||
| Blinded set | 599 | 3 | Set to validate aGvHD pattern |
| Day 0 | 64 | 4 | Omitted from classification |
| Total | 663 | ||
| Total | 797 |
| Clinical condition . | Patients, n . | Group no. . | Use . |
|---|---|---|---|
| Training set | |||
| aGvHD | 13 | 1 | Training set to develop GvHD pattern |
| Control | 50 | 1 | Training set to develop GvHD pattern |
| Total | 63 | ||
| Chronic renal disease | |||
| Healthy | 20 | 2 | Set to develop GvHD pattern specificity |
| IgAN | 24 | 2 | Set to develop GvHD pattern specificity |
| DN | 11 | 2 | Set to develop GvHD pattern specificity |
| FSGS | 6 | 2 | Set to develop GvHD pattern specificity |
| MCD | 8 | 2 | Set to develop GvHD pattern specificity |
| MGN | 5 | 2 | Set to develop GvHD pattern specificity |
| Vasculitis | 11 | 2 | Set to develop GvHD pattern specificity |
| SLE | 4 | 2 | Set to develop GvHD pattern specificity |
| Total | 71 | ||
| Blinded set | 599 | 3 | Set to validate aGvHD pattern |
| Day 0 | 64 | 4 | Omitted from classification |
| Total | 663 | ||
| Total | 797 |
Healthy indicates healthy control; IgAN, IgA nephropathy; DN, diabetic nephropathy; FSGS, focal-segmental glomerulosclerosis; MCD, minimal change disease; MGN, membranous nephropathy; and SLE, systemic lupus erythematodes.